Comparing heart disease risk estimates for Orforglipron using two prediction models

Orforglipron improves multiple cardiometabolic risk factors.

• Previous evaluations of Orforglipron's cardiovascular benefits utilized the 2013 Pooled Cohort Equations.
• The 2013 equations do not consider body mass index (BMI), estimated glomerular filtration rate (eGFR), or hemoglobin A1c (HbA1c).
• The 2023 AHA PREVENT equations incorporate these additional variables for a more comprehensive assessment.
• Re-evaluating Orforglipron's benefits using the newer equations may provide a clearer understanding of its impact.

Simplified